Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBH

- PMLiVE

Health coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Patient involvement in health technology assessment

Patients can improve the quality, relevance and value of HTA for all pharma stakeholders

- PMLiVE

A unique ecosystem

How life science and healthcare clusters are driving innovation

Novartis Oncology head Bruno Strigini to retire

Will leave the Swiss pharma firm, and the industry, next year

- PMLiVE

New NHS Alliance launches healthcare TV programme

In Search of Wellness follows those on a quest to improve healthcare

- PMLiVE

CAR-T therapies show long-term benefits in lymphoma

Novartis’ Kymriah and Gilead’s Yescarta both achieve significant complete response in lymphoma patients

- PMLiVE

AAA board presses go on $3.9bn Novartis takeover

French radiopharmaceuticals firm backs the cash offer

Social Media and Health: the Cure or the Disease?

Social media is going through a crisis. So is this the right time for the pharma industry to join the conversation?

Life Healthcare Communications

- PMLiVE

EU’s first health report card – must do better

Report implies Europe must shift its focus to disease prevention

- PMLiVE

Is AI changing the future of healthcare?

How technology is playing a big role in healthcare

- PMLiVE

Novartis’ orphan drug Tasigna wins EU expanded indication

The CML medication can now treat paediatric patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links